ArticleComputational and structural biotechnology journal2025
From shadows to clarity: A new paradigm for comprehensive variant detection in undiagnosed dystrophinopathy using combined long-read and RNA sequencing.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 2-5 % of dystrophinopathy cases remain undiagnosed at the molecular level following standard multiplex ligation-dependent probe amplification (MLPA) and exome sequencing (ES), precluding these patients from variant-specific genetic counseling and therapy eligibility assessment. We developed an integrated diagnostic pipeline combining targeted long-read sequencing (LRS) with muscle RNA-seq and applied it to 50 Chinese patients (46 males, 4 females) with biopsy-confirmed dystrophinopathy in whom MLPA and ES had yielded negative results. A molecular diagnosis was achieved for all 50 probands: 30 (60 %) harbored intronic single nucleotide variants (SNVs) leading to pseudoexon inclusion or exon skipping, while the remaining 20 (40 %) carried complex structural variants (SVs), including inversions (n = 13), translocations (n = 5), and insertions/deletions (n = 2). Of these, 23 (46 %) were novel variants not previously recorded in disease databases, and RNA-seq confirmed their aberrant splicing effects. A notable discovery was a 1.9 kb intronic inversion that uniquely activated cryptic splice sites on the antisense strand, representing a previously unreported pathogenic mechanism in dystrophinopathies. Cascade screening identified 45 carriers across 28 families, revealing a maternal carrier rate of 84.8 % (28/33). This integrated LRS and RNA-seq approach demonstrates significant value in resolving molecularly undiagnosed dystrophinopathy cases and enabling comprehensive genetic counseling. Furthermore, it establishes a robust diagnostic paradigm for molecularly unresolved neuromuscular disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.